INT351501

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2010
Last Reported 2010
Negated 7
Speculated 3
Reported most in Body
Documents 18
Total Number 30
Disease Relevance 12.50
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (IKBKAP) nucleolus (IKBKAP) nucleus (IKBKAP)
protein complex assembly (IKBKAP) DNA binding (IKBKAP) cytoplasm (IKBKAP)
Anatomy Link Frequency
fibroblasts 1
IKBKAP (Homo sapiens)
Pain Link Frequency Relevance Heat
Potency 30 14.80 Low Low
Peripheral nervous system 19 9.24 Low Low
imagery 38 5.00 Very Low Very Low Very Low
Pain 30 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Familial Dysautonomia 3124 100.00 Very High Very High Very High
Apoptosis 49 98.80 Very High Very High Very High
Toxicity 55 98.62 Very High Very High Very High
Targeted Disruption 57 95.84 Very High Very High Very High
Congenital Anomalies 22 93.60 High High
Rare Diseases 38 92.56 High High
Neuropathic Pain 41 92.04 High High
Embryonic Lethality 19 77.72 Quite High
Cognitive Disorder 77 74.64 Quite High
Neurodegenerative Disease 30 73.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The choline-based substance had little effect on the level of IKAP mRNA.
Neg (little) Regulation (effect) of IKAP mRNA
1) Confidence 0.62 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.66 Pain Relevance 0
This is probably because PS affects transcription rather than IKAP function directly.
Regulation (affects) of IKAP
2) Confidence 0.62 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.23 Pain Relevance 0
A possible explanation for lower efficacy at higher PS concentration is the toxicity of the solvent at high volumes, although the solvent itself did not affect IKAP mRNA levels (data not shown).
Neg (not) Regulation (affect) of IKAP mRNA associated with toxicity
3) Confidence 0.62 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.33 Pain Relevance 0
We thus examined the effect of PS on the level of IKAP mRNA in FDB cells after 3, 7 and 14 days of treatment.
Spec (examined) Regulation (effect) of IKAP mRNA
4) Confidence 0.62 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.28 Pain Relevance 0
In addition, kinetin has no significant effects on IKBKAP transcript levels in control cells, which likely excludes a potential action of kinetin on IKBKAP transcription.
Neg (no) Spec (likely) Regulation (effects) of IKBKAP
5) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.17 Pain Relevance 0
In order to determine how fast kinetin modulates IKBKAP mRNA splicing, we performed a time-course experiment with a constant concentration of 80 ┬ÁM over 24 h.
Spec (determine) Regulation (modulates) of IKBKAP
6) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.36 Pain Relevance 0
This suggests that IKBKAP alternative splicing may not be the only pathological alteration in FD.
Regulation (alteration) of IKBKAP associated with familial dysautonomia
7) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.37 Pain Relevance 0
The new model described in this study will allow us further test whether candidate splicing factors may be involved in the tissue-specific regulation of IKBKAP mRNA alternative splicing.


Regulation (regulation) of IKBKAP
8) Confidence 0.61 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.44 Pain Relevance 0
This suggests that IKBKAP alternative splicing may not be the only pathological alteration in FD.
Regulation (alteration) of FD associated with familial dysautonomia
9) Confidence 0.53 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.36 Pain Relevance 0
Surprisingly, we did not find IKBKAP as a dysregulated gene in our microarray analysis.
Regulation (dysregulated) of IKBKAP
10) Confidence 0.53 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.63 Pain Relevance 0
This may mean that the IKAP protein is directly or indirectly involved in cell cycle checkpoint regulation, and the reduced levels of IKAP in FD cells results in abnormal growth of cells.
Regulation (involved) of IKAP protein associated with familial dysautonomia
11) Confidence 0.45 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.78 Pain Relevance 0
The mutation observed in almost all FD patients is a point mutation at position 6 of intron 20 of the IKBKAP gene; this gene encodes the I?
Regulation (intron) of IKBKAP associated with familial dysautonomia
12) Confidence 0.45 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC3012102 Disease Relevance 0.67 Pain Relevance 0
To address the question of a possible PCR artifact or lowered microarray sensitivity and because the FD mutation is located in the middle region of the IKBKAP gene, we performed quantitative PCR at both ends of the IKBKAP gene.
Regulation (ends) of IKBKAP associated with familial dysautonomia
13) Confidence 0.45 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.47 Pain Relevance 0
The number of IKBKAP and ABL1 transcripts was extrapolated automatically by the Sequence Detection System v2.2.2 software (Applied Biosystems).


Regulation (extrapolated) of IKBKAP
14) Confidence 0.45 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.08 Pain Relevance 0
We also demonstrated that long time culture conditions and trypsin-EDTA mediated cell passages did not affect the IKBKAP gene expression pattern.
Neg (not) Regulation (affect) of IKBKAP
15) Confidence 0.45 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.58 Pain Relevance 0
Interestingly, like previous studies, we observed that a majority of genes were down-regulated in FD hOE-MSCs (Table 1, negative values), and only 4 genes were up-regulated (Table 1 and Table S1, positive values).
Regulation (regulated) of FD associated with familial dysautonomia
16) Confidence 0.39 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.30 Pain Relevance 0
Since we and others [22], [40] did not detect IKBKAP among the significantly down-regulated transcripts in FD compared to control samples, we asked whether this discrepancy could be due to a lack of sensitivity of microarray compared to RT-qPCR.
Regulation (regulated) of FD associated with familial dysautonomia
17) Confidence 0.39 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3004942 Disease Relevance 0.64 Pain Relevance 0
It is possible that the PS-induced increase in TM4SF1 mRNA levels increases IKAP levels through regulation involving cell migration, which is impaired in Elongator-depleted cells [20].
Regulation (regulation) of IKAP
18) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.27 Pain Relevance 0
These results indicate that the effect of PS on the level of IKAP mRNA differed among FD cell lines.
Regulation (effect) of IKAP mRNA associated with familial dysautonomia
19) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.17 Pain Relevance 0
Since FD is characterized by defects in the Elongator complex, involved in transcription elongation [13], [15], PS may affect IKAP levels through regulation of transcriptional elongation.
Regulation (regulation) of IKAP associated with familial dysautonomia
20) Confidence 0.27 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012102 Disease Relevance 0.25 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox